Loading people...
Dave Maki currently serves as the Managing Partner at Altitude Life Science Ventures, an early-stage venture capital firm based in Seattle, Washington. Prior to founding the investment firm, he served as the Managing Partner at Seed IP Law Group, where he specialized in intellectual property strategy for the biotechnology and pharmaceutical sectors. Holding a Juris Doctor degree, he leverages his extensive background in patent law to identify, fund, and build emerging life science companies across the Pacific Northwest region. Through Altitude Life Science Ventures, he has directed capital into several successful regional startups that achieved significant initial public offerings and major acquisitions, including Alder Biopharmaceuticals, which was acquired by Lundbeck in 2019, and Ikaria. As an investor, his current focus remains on portfolio construction, deal sourcing, and guiding early-stage scientific and medical innovation toward successful commercialization.
Dave Maki is a distinguished Managing Partner at Altitude Life Science Ventures (ALSV), a leading venture capital firm committed to transforming healthcare through strategic investments. At ALSV, Dave Maki plays a pivotal role in identifying, evaluating, and nurturing early-stage companies poised to make significant impacts across the life science landscape. His leadership is instrumental in guiding ALSV's investment strategy, ensuring capital is deployed to the most promising and innovative ventures.
ALSV, under Dave Maki's guidance, primarily focuses on a diverse range of life science sectors. These include cutting-edge biotechnology, revolutionary medical devices (medtech), and advancements in pharmaceuticals. Dave Maki and his team are particularly interested in companies developing novel therapeutics, diagnostics, digital health solutions, and platform technologies that address unmet medical needs. The firm seeks out founders with strong scientific foundations and clear pathways to commercialization, aiming to support them from seed stage through Series A and beyond.
Dave Maki brings a wealth of experience and a deep understanding of the life science ecosystem to his role. His career background is marked by a strong track record in venture capital, corporate development, and strategic partnerships within the healthcare and biotech industries. Prior to joining Altitude Life Science Ventures, Dave Maki held key positions where he was responsible for identifying disruptive technologies, structuring complex deals, and driving growth for emerging companies. This extensive background has equipped him with a unique perspective on market dynamics, regulatory pathways, and the critical factors for success in the highly competitive life science arena.
While specific notable investments are proprietary to ALSV's portfolio, Dave Maki's influence is evident in the firm's commitment to backing companies that are not only scientifically sound but also possess strong commercial viability. He is known for his hands-on approach, working closely with portfolio companies to provide strategic guidance, operational support, and access to a vast network of industry experts. His dedication ensures that ALSV's investments are not just financial transactions but true partnerships aimed at accelerating scientific discovery and bringing life-changing solutions to patients worldwide.
Dave Maki's vision for Altitude Life Science Ventures is clear: to be a catalyst for innovation, empowering entrepreneurs to overcome challenges and achieve their full potential. His expertise and strategic acumen make him a key figure in the venture capital community, driving progress in the vital field of life sciences.
Dave Maki is the Managing Partner at Altitude Life Science Ventures (ALSV), a prominent venture capital firm. He is a key leader in identifying and investing in innovative early-stage life science companies.
Dave Maki, through Altitude Life Science Ventures (ALSV), invests in a broad spectrum of life science sectors. His focus includes biotechnology, medical devices (medtech), and pharmaceuticals, targeting novel therapeutics, diagnostics, and digital health solutions.
Dave Maki works as the Managing Partner at Altitude Life Science Ventures (ALSV), a venture capital firm dedicated to investing in and fostering growth within the life science industry.
